Complete AI Training
Start for Free

Your job's AI kit

Get your AI kit

Tell us who you are and what you do. We show you your kit right away and email you the link: skills, prompts, AI agents, MCP servers and courses for your job.

500+ jobs ready, and we make a kit for any other job. No payment needed to look.

Share

AI news ·

MSD and Isomorphic Labs partner on AI-driven oncology drug discovery

MSD and Isomorphic Labs struck a drug-discovery deal with an upfront payment, milestones, and tiered royalties, plus an option for Isomorphic to co-fund for higher payouts.

MSD and Isomorphic Labs announced a strategic research collaboration on November 19, 2026, combining Isomorphic Labs' AI-driven drug design engine with MSD's proprietary data and discovery expertise. The deal includes an upfront payment to Isomorphic Labs, milestone payments, and tiered royalties, with an option for Isomorphic Labs to co-fund development in exchange for higher royalties.

The partnership will target an oncology program of strategic importance. Isomorphic Labs will generate in silico predictions and molecular designs using its IsoDDE platform, trained on select high-quality data sets from MSD. MSD will handle preclinical and clinical development, manufacturing, and commercialization of any resulting products.

How the collaboration divides the work

The agreement separates computational design from physical development. Isomorphic Labs focuses on the "dry-lab" - the modeling and simulation that predicts how molecules will behave. MSD takes responsibility for the "wet-lab" validation, regulatory processes, and bringing a drug to market. The structure lets each organization operate where it has the deepest capability.

George Addona, senior vice president and head of discovery, preclinical development and translational medicine at MSD Research Laboratories, described the logic behind the split. "The key to successfully leveraging AI/ML for molecular invention lies in close coordination of wet-lab and dry-lab functions," he said. "By combining MSD's substantial internal data capabilities and discovery expertise with Isomorphic Labs' powerful modeling and compute capabilities, we aim to identify new ways to design and create better candidates faster."

The technology behind the deal

Isomorphic Labs, founded in 2021 and led by CEO Sir Demis Hassabis, built the IsoDDE as a modality-agnostic drug design engine. The system uses foundational AI models to predict molecular behavior across novel biological targets. The company operates from London, Cambridge, Massachusetts, and Lausanne, Switzerland, advancing both partnered and internal drug programs.

For researchers working at the intersection of AI and drug discovery, the collaboration signals how large pharmaceutical companies are structuring external AI partnerships. Rather than building everything in-house, MSD is pairing its internal data - often the scarcest resource in this field - with an external team's specialized computational models. AI R&D Engineering Courses increasingly cover the kind of molecular modeling and simulation workflows that underpin deals like this one.

What the deal is worth

Neither company disclosed the upfront payment amount or the specific milestone thresholds. Isomorphic Labs will receive payments tied to research, development, regulatory, and commercial milestones, plus tiered royalties on net sales. The co-funding option gives Isomorphic Labs a path to larger royalty percentages if it chooses to share development costs.

Sarah Skerratt, chief research officer at Isomorphic Labs, framed the collaboration around the difficulty of the target. "Through this collaboration with MSD, we will apply our world-leading drug design engine to unlock significant discovery progress," she said. "By leveraging the generative and predictive power of the IsoDDE to address this challenging program, this collaboration highlights our companies' shared commitment to innovation for the benefit of patient populations with unmet needs."

Why this matters for healthcare and research professionals

This deal reflects a maturing model for AI-in-biopharma partnerships: the pharma company supplies proprietary data and development muscle, while the AI firm supplies the computational engine and predictive models. For scientists and research managers, the practical takeaway is that AI collaboration agreements are moving beyond proof-of-concept into single-target, milestone-structured deals with real financial terms. The skills needed to evaluate, structure, or contribute to these collaborations - particularly understanding what makes proprietary data valuable to a modeling partner - are becoming as important as traditional discovery expertise.

Share